Eli Lilly and Company $LLY Stake Decreased by Calamos Wealth Management LLC

Calamos Wealth Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 15.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 31,292 shares of the company’s stock after selling 5,659 shares during the quarter. Eli Lilly and Company comprises approximately 1.0% of Calamos Wealth Management LLC’s holdings, making the stock its 19th largest position. Calamos Wealth Management LLC’s holdings in Eli Lilly and Company were worth $28,782,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC grew its position in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares in the last quarter. Basso Capital Management L.P. bought a new stake in Eli Lilly and Company in the fourth quarter worth $30,000. Finally, Maseco LLP boosted its stake in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after acquiring an additional 28 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Royal Bank Of Canada raised their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 8th. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Leerink Partners raised their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Guggenheim raised their price target on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a report on Monday. Finally, UBS Group increased their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,268.78.

Eli Lilly and Company Stock Down 0.2%

Shares of LLY opened at $1,185.71 on Tuesday. The firm has a market cap of $1.12 trillion, a P/E ratio of 42.12, a price-to-earnings-growth ratio of 1.47 and a beta of 0.51. The firm’s 50-day simple moving average is $1,103.63 and its 200 day simple moving average is $1,034.03. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the company posted $3.34 EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.81 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Guggenheim raised its price target on Eli Lilly to $1,273 and reiterated a Buy rating, reinforcing Wall Street’s confidence in the company’s growth outlook. Benzinga
• Positive Sentiment: Eli Lilly is presenting new Kisunla data at the Alzheimer’s Association International Conference, giving investors another potential pipeline catalyst beyond its blockbuster weight-loss drugs. Benzinga
• Positive Sentiment: Commentary around Eli Lilly’s obesity drugs continues to highlight how important the franchise is to revenue, with two products now generating nearly two-thirds of sales — a reminder of the company’s scale and earnings power. The Motley Fool
• Neutral Sentiment: Cathie Wood’s ARK funds added Eli Lilly alongside other large-cap names, which may signal continued institutional interest but is not a direct company-specific catalyst. Yahoo Finance
• Neutral Sentiment: Social-media and trading chatter remains upbeat, with investors citing upgraded targets and biotech momentum, but these comments are sentiment-driven rather than new fundamental disclosures. Quiver Quantitative
• Neutral Sentiment: A 247WallSt piece argues there may be a new under-the-radar catalyst in Eli Lilly’s pipeline, but it is largely speculative and not a confirmed development. 247WallSt

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.